---
title: "Larimar Therapeutics director Thomas Edward Hamilton acquires USD 166,890 of common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292109333.md"
description: "Larimar Therapeutics director Thomas Edward Hamilton acquired 50,000 common shares at a weighted-average price of $3.34, totaling USD 166,890. This transaction increased his direct common stock holdings to 714,798 shares. Additionally, he holds 159,433 shares indirectly through Post Edison, LLC. The disclosure was filed via EDGAR on July 8, 2026."
datetime: "2026-07-08T20:06:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292109333.md)
  - [en](https://longbridge.com/en/news/292109333.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292109333.md)
generator: "portal-rs"
---

# Larimar Therapeutics director Thomas Edward Hamilton acquires USD 166,890 of common shares

-   Larimar Therapeutics director Thomas Edward Hamilton bought 50,000 common shares at a weighted-average price of $3.34. \* Direct common stock holdings rose to 714,798 shares. \* He also reported 159,433 shares held indirectly through Post Edison, LLC. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-298523), on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)

## Related News & Research

- [Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR](https://longbridge.com/en/news/295771398.md)
- [Larimar Therapeutics Q2 net loss widens to $32.78 million; R&D expenses rise to $28 million](https://longbridge.com/en/news/294812276.md)
- [Light & Wonder director Jamie Odell disposes of USD 9.26 million in common shares](https://longbridge.com/en/news/296414548.md)
- [TIP buys 146,940 shares at weighted average price of EUR 9.92 under buyback program](https://longbridge.com/en/news/296074805.md)
- [Agilysys Insiders Sold Shares Worth Over $1.6M](https://longbridge.com/en/news/296401909.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**